Johnson & Johnson (NYSE:JNJ) Shares Sold by Mill Creek Capital Advisors LLC

Mill Creek Capital Advisors LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 3.1% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 255,148 shares of the company’s stock after selling 8,225 shares during the period. Johnson & Johnson accounts for approximately 0.9% of Mill Creek Capital Advisors LLC’s portfolio, making the stock its 18th biggest holding. Mill Creek Capital Advisors LLC’s holdings in Johnson & Johnson were worth $37,292,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of JNJ. Innealta Capital LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $27,000. Vermillion & White Wealth Management Group LLC purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $44,000. MFA Wealth Advisors LLC acquired a new position in Johnson & Johnson during the second quarter worth $43,000. Grayhawk Investment Strategies Inc. increased its stake in shares of Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the last quarter. Finally, Fairfield Financial Advisors LTD purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth $46,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $163.21 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a market cap of $392.79 billion, a P/E ratio of 10.18, a PEG ratio of 2.71 and a beta of 0.53. The firm’s 50 day moving average price is $161.58 and its 200 day moving average price is $154.15.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same period last year, the firm earned $2.80 earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s payout ratio is 30.92%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research report on Friday. The Goldman Sachs Group reduced their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Morgan Stanley increased their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Finally, Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.